The American Kratom Association is urging the nation’s most influential physician group to draw a firm regulatory and scientific line between traditional kratom leaf and a new wave of products chemically engineered to deliver high doses of the opioid-like compound 7-hydroxymitragynine.
In a recent statement, the advocacy group said the American Medical Association’s move to back tighter controls on highly concentrated 7-OH products is warranted, particularly to protect children and adolescents, but warned that describing these lab-altered substances as “kratom products” risks misleading the public and lawmakers about what consumers actually encounter when they purchase raw leaf or conventional kratom powder.
The debate comes as kratom, derived from the leaves of the Southeast Asian tree Mitragyna speciosa, continues its spread in the United States, where millions of adults use teas, capsules, and powders for energy, mood, or self-managed pain relief.
At its annual meeting, the AMA adopted a policy that explicitly targets products containing concentrated 7-hydroxymitragynine, often shortened to 7-OH, calling for a ban on the sale, distribution, or marketing of such items and urging federal and state regulators to treat them as adulterated or misbranded, especially when they are formulated and presented in ways that appeal to minors.
The AMA policy underscores that 7-OH is a potent opioid-like compound that occurs only in trace amounts in the kratom plant but can be isolated, concentrated, or chemically generated to create products that may bear little resemblance to the traditional preparations used in countries like Thailand and Malaysia, where kratom leaves have been chewed or brewed as tea for generations.
The American Kratom Association, which has long positioned itself as a consumer protection and education group, says it supports strict controls on these lab-manipulated 7-OH formulations, but argues that grouping them under the broad label of kratom muddies the evidence on risks associated with natural leaf and could drive policy that effectively criminalizes the plant while failing to address the separate category of synthetic or chemically altered derivatives.
The group points to an emerging body of research showing that natural kratom products are primarily composed of mitragynine, the plant’s dominant alkaloid, with 7-hydroxymitragynine present only in small quantities, a distinction echoed in reference materials for clinicians such as the StatPearls monograph on kratom, which notes that mitragynine is the most prevalent active compound while 7-OH, although more potent at opioid receptors, typically appears as an oxidized metabolite.
The National Institute on Drug Abuse similarly describes mitragynine as the best studied kratom alkaloid and explains that when ingested, it can be metabolized into 7-hydroxymitragynine, reinforcing the idea that a natural product’s pharmacology is rooted in a complex mixture dominated by mitragynine rather than by large, pre-formed quantities of 7-OH.
By contrast, regulators and researchers have begun documenting products marketed as kratom extracts that contain unusually high concentrations of 7-hydroxymitragynine achievable only through synthetic manipulation, with one recent analysis in the biomedical literature finding that some items sold as “kratom extract” were in fact unapproved new drugs featuring elevated 7-OH levels and other constituents not present in native leaf, raising significant public health concerns.
In that study, investigators emphasized the urgent need to differentiate traditional kratom leaf from these high-7-OH products, noting that the latter are not authentic kratom extracts but synthetic derivatives whose labeling can mislead consumers and complicate efforts to craft sensible regulatory approaches.
For the American Kratom Association, this emerging scientific record supports its call for regulators and the medical community to treat altered 7-OH opioids as a separate category, distinct from the teas, capsules, and powders made from crushed or ground leaf that dominate the legal kratom market today.
The association argues that failure to make this distinction could push policymakers toward sweeping bans that treat all kratom products as if they carry the same risk profile as concentrated 7-OH formulations, an outcome the group contends would ignore both traditional use patterns and the controlled human data now beginning to appear in the literature.
Among the evidence the group cites is an FDA-supervised human pharmacokinetic study in which adult participants consumed substantial doses of kratom leaf under clinical observation, allowing researchers to track mitragynine and 7-OH levels in the bloodstream and assess short-term safety outcomes.
In that trial, which examined both single and multiple dosing regimens, mitragynine levels rose proportionally with dose and reached steady state over several days, while 7-hydroxymitragynine appeared at lower concentrations, and investigators reported that the kratom leaf preparations used were generally well tolerated without serious adverse events among the healthy adult volunteers enrolled.
The study’s authors stressed that their work was not designed to endorse kratom for any medical use, but rather to provide detailed pharmacokinetic data and preliminary safety observations, and they emphasized the need for additional research into long-term use, dependence, and interactions with other substances, a point public health agencies like the National Institute on Drug Abuse have also underscored.
Still, for kratom advocates, including the American Kratom Association, the finding that adults could tolerate significant doses of natural kratom leaf without acute severe toxicity under medical supervision strengthens the case for regulating traditional kratom separately from products deliberately engineered to maximize 7-OH exposure.
The association contrasts this with the AMA’s focus on concentrated 7-OH, arguing that while the physician group’s concern about opioid-like harms to minors is justified, public messaging should clearly signal that these products are chemically manipulated opioids, not merely a stronger version of the kratom teas or powders sold in many smoke shops and online stores.
The AMA, for its part, has framed its policy as a public health response to a rapidly evolving marketplace, where manufacturers are increasingly extracting and concentrating 7-OH into candies, gummies, and other child-friendly forms, and has urged the U.S. Food and Drug Administration and state legislatures to move quickly to classify such items as adulterated or misbranded when offered in ways that are accessible to minors.
The Food and Drug Administration has already taken a hard line on certain kratom-related products, issuing warning letters and, in some cases, recommending that potent derivatives like 7-hydroxymitragynine be treated as controlled substances, while reiterating that no kratom or kratom-based product is approved as a drug or dietary supplement, as reflected in the agency’s public safety communications available through its consumer updates on kratom.
Public health researchers have also highlighted the complexity of kratom’s risk profile, noting in reviews published through platforms like the National Institutes of Health’s PubMed Central that while traditional kratom preparations do not appear to cause the same kind of respiratory depression associated with many classical opioids, concerns remain about dependence, withdrawal, and toxicity from adulterated or highly concentrated products.
Those reviews distinguish between dried leaf powders and teas, on the one hand, and potent extracts and novel formulations on the other, warning that the latter can vary widely in their content of mitragynine and minor alkaloids like 7-hydroxymitragynine, making it difficult for consumers and clinicians alike to predict how a given product will behave in the body.
As lawmakers in multiple states consider bans, age restrictions, or regulated access frameworks, the American Kratom Association is pressing for what it calls “evidence-based differentiation,” advocating model laws that set manufacturing standards and require testing and labeling for kratom leaf products while separately addressing synthetic or chemically altered derivatives that fall outside the historical and botanical definition of kratom.
The group’s pushback against the AMA reflects a broader battle over how to categorize and control emerging psychoactive substances that occupy a gray area between traditional herbal use and modern pharmaceutical-style engineering, with researchers, regulators, and industry all jockeying to shape the narrative around risk and benefit.
For consumers, the dispute highlights the importance of understanding not just the word “kratom” on a label but the underlying chemistry of the product in the bottle, a task made more challenging by a patchwork of state laws and the absence of a comprehensive federal regulatory framework that clearly distinguishes between natural leaf, conventional extracts, and synthetically fortified 7-OH formulations.
Clinicians, meanwhile, are being asked to navigate a landscape in which patients may present with kratom use histories that range from modest, long-term consumption of powdered leaf to recent exposure to high-potency 7-OH products, underscoring the need for continuing education through resources such as the NCBI Bookshelf’s clinical overviews and ongoing updates from professional bodies like the AMA.
As the science continues to evolve, the core question at the center of the American Kratom Association’s challenge to the AMA is whether regulators, physicians, and the public will recognize a clear boundary between centuries-old kratom practices and the distinct category of chemically manipulated 7-OH opioids, or whether both will be swept into a single policy response that could redefine the future of kratom in the United States.